Soliris opens the C5 market (2007)
Alexion's eculizumab became the first drug approved to block complement protein C5, for a rare blood disorder called paroxysmal nocturnal hemoglobinuria. A decade later the FDA cleared it for generalized myasthenia gravis.
A rare-disease drug priced in the hundreds of thousands of dollars a year turned Alexion into a major biotechnology company.
C5 became one of the most contested targets in drug development, and AstraZeneca bought Alexion in 2021.
Livsayis enters a C5 market that Soliris created and that now holds several competitors, including AstraZeneca's own products.
